RxSight, Inc. (RXST) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. RxSight, Inc. is a commercial-stage medical technology company developing and selling the RxSight Light Adjustable Lens (LAL) system for cataract surgery. The system includes the LAL intraocular lens and the Light Delivery Device (LDD). The company operates in a single reportable segment and is headquartered in Aliso Viejo, California.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Sales | $33.6 million | $34.9 million | $71.5 million | $64.4 million |
| Gross Profit | $25.2 million | $24.3 million | $53.5 million | $44.9 million |
| Gross Margin | 74.9% | 69.5% | 74.8% | 69.8% |
| Net Loss | $(11.8) million | $(6.1) million | $(20.0) million | $(15.2) million |
| Loss Per Share (Basic/Diluted) | $(0.29) | $(0.16) | $(0.49) | $(0.40) |
| Cash & Short-Term Investments | $227.5 million (as of June 30, 2025) | |||
| Accumulated Deficit | $642.1 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Mix Shift: Q2 2025 sales decreased 3.6% year-over-year primarily due to a 49% drop in LDD unit sales (40 units vs. 78 units). This decline was partially offset by a 13% increase in LAL sales (27,380 units vs. 24,214 units), driven by a larger installed base.
- Margin Expansion: Gross margin improved to 74.9% in Q2 2025 from 69.5% in Q2 2024. This was driven by a favorable product mix (higher percentage of high-margin LAL sales) and improved operating leverage.
- Expense Growth: Operating expenses increased significantly. Selling, General, and Administrative (SG&A) expenses rose 19.3% to $29.0 million, and Research and Development (R&D) expenses rose 23.2% to $10.2 million. Increases were attributed to higher headcount, stock-based compensation, and post-market study costs.
- Net Loss Widening: The net loss for Q2 2025 more than doubled compared to the prior year period, increasing from $6.1 million to $11.8 million, reflecting the combination of lower revenue and higher operating costs.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($227.5 million) are sufficient to fund operations for at least the next 12 months. The company does not currently anticipate the need to raise additional capital to reach profitability but may do so opportunistically.
- Operational Strategy: The company has realigned its commercial structure, unifying LAL sales and clinical support into a "Customer Success Organization" to drive utilization growth at existing accounts. The LDD sales team remains focused on acquiring new high-potential accounts.
- Legal Contingency: A putative securities class action lawsuit (Makaveev v. RxSight, Inc.) was filed on July 22, 2025, alleging false statements regarding product demand and financial guidance. The company denies the allegations and intends to defend vigorously.
- Risks: Key risks include supply chain constraints (reliance on single/sole source suppliers), potential tariffs on imported components, regulatory changes (including the new FDA Quality Management System Regulation effective Feb 2026), and the outcome of the pending securities litigation.
Investor Verification Checklist
- LDD Sales Trajectory: Verify the sustainability of the 49% year-over-year decline in LDD sales and the effectiveness of the new "Customer Success" strategy in reversing this trend.
- Installed Base Utilization: Confirm the correlation between the growing LDD installed base (1,084 units) and the rate of LAL implantation to ensure revenue growth is not solely dependent on new device sales.
- Legal Exposure: Monitor developments in the Makaveev securities class action filed in July 2025 for potential financial impact or reputational damage.
- Supply Chain Resilience: Assess the company's mitigation strategies for single-source supplier risks and potential tariff impacts on cost of sales.
- Cash Burn Rate: Track the quarterly cash burn rate against the $227.5 million liquidity position to validate the 12-month runway assertion.